Mark S. Freedman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark S. Freedman has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Uccelli
IRCCS Ospedale Policlinico San Martino Genoa Italy
2 shared publications G Comi
Centro Sclerosi Multipla, Ospedale San Raffaele, Milan, Italy
2 shared publicationsMohammad Sharief
2 shared publicationsA Dukler
Glycominds Ltd, 1 Yodfat St, Alon Bldg, Lod 71291, Israel
1 shared publication- Adam F. Carpenter
The GWI and HLA Research Groups, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN 55417, USA
1 shared publication Ahmad Al-Sabbagh
1 shared publication
Latest Publications
- Open Access
- 1 November 2014
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 3 (6) , 696-704
Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study
- 1 November 2014
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 3 (6) , 696-704
Open AccessHuman placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study
- Open Access
- 15 November 2013
- Published by Wiley in European Journal of Neurology
- Vol. 21 (3) , 377-e20
Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon‐β therapy
Background and purpose: Although the first‐line disease‐modifying therapies (DMTs) interferon beta and glatiramer acetate have a favourable benefit‐to‐risk profile, they are only partially effective for treating relapsing–remitting multiple sclerosis (RRMS). The optimization of treatment in patients who do not show a maximum response to first‐line therapy is critical for achieving the best long‐term outcomes. Treatment strategies for patients with a suboptimal response include switching to another first‐line DMT or a second‐line DMT. Natalizumab and fingolimod are approved for RRMS with high disease activity in the European Union and Canada.Methods: A comprehensive literature search for articles published between 1990 and April 2012 was undertaken.Results: This review discusses key clinical and safety data for fingolimod and natalizumab, particularly in the patient subgroups for whom these treatments are approved. Benefit‐to‐risk profiles, including first‐dose cardiovascular effects associated with fingolimod and the risk of progressive multifocal encephalopathy with natalizumab, are discussed.Conclusion: A descriptive comparison of fingolimod and natalizumab is provided in the context of the decision‐making process of how and when to switch patients who have a suboptimal response to first‐line therapy.
- 15 November 2013
- Published by Wiley in European Journal of Neurology
- Vol. 21 (3) , 377-e20
Open AccessTreatment options for patients with multiple sclerosis who have a suboptimal response to interferon‐β therapy
Background and purpose: Although the first‐line disease‐modifying therapies (DMTs) interferon beta and glatiramer acetate have a favourable benefit‐to‐risk profile, they are only partially effective for treating relapsing–remitting multiple sclerosis (RRMS). The optimization of treatment in patients who do not show a maximum response to first‐line therapy is critical for achieving the best long‐term outcomes. Treatment strategies for patients with a suboptimal response include switching to another first‐line DMT or a second‐line DMT. Natalizumab and fingolimod are approved for RRMS with high disease activity in the European Union and Canada.Methods: A comprehensive literature search for articles published between 1990 and April 2012 was undertaken.Results: This review discusses key clinical and safety data for fingolimod and natalizumab, particularly in the patient subgroups for whom these treatments are approved. Benefit‐to‐risk profiles, including first‐dose cardiovascular effects associated with fingolimod and the risk of progressive multifocal encephalopathy with natalizumab, are discussed.Conclusion: A descriptive comparison of fingolimod and natalizumab is provided in the context of the decision‐making process of how and when to switch patients who have a suboptimal response to first‐line therapy.
- Open Access
- 10 January 2012
- Published by Elsevier in The Lancet Neurology
- Vol. 11 (2) , 123-125
Neurorepair with mesenchymal stem cells: hope or hype?
- 10 January 2012
- Published by Elsevier in The Lancet Neurology
- Vol. 11 (2) , 123-125
Open AccessNeurorepair with mesenchymal stem cells: hope or hype?
- 1 December 2011
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 1 (1) , 66-68
Multiple sclerosis therapeutic strategies
- 1 December 2011
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 1 (1) , 66-68
Multiple sclerosis therapeutic strategies
- 4 January 2011
- Published by Wolters Kluwer Health in Neurology
- Vol. 76 (1_suppleme) , S35-S38
Improving long-term follow-up studies of immunomodulatory therapies
Goals in the treatment of multiple sclerosis (MS) focus on reducing symptoms and disease progression. Registry data indicate that the accumulation of significant disability can take decades. Therefore, long-term follow-up (LTFU) studies are needed to understand the impact of disease-modifying therapy (DMT) in MS. Based on analyses of available LTFU study data, recommendations for future LTFU studies can be made. A disability milestone may be considered because exploratory data show that DMT may slow the progression of disability. Achievement of the EDSS steps 4 or 6 may be sufficient milestones because, once reached, MS progresses inevitably. Since a placebo control cannot be ethically used in LTFU studies, a standard-of-care comparator could be considered. The ideal LTFU study should be performed according to the highest possible standards. A high-quality LTFU study would achieve high retention rates, capture complete data at prespecified assessment intervals, and be powered to the key outcome measure. In addition, propensity scoring is an approach used to reduce bias in treatment comparisons in observational studies and might be a suitable approach for analyzing LTFU studies. With careful consideration of LTFU limitations and study design, it is possible to attain a high degree of rigor in future studies.
- 4 January 2011
- Published by Wolters Kluwer Health in Neurology
- Vol. 76 (1_suppleme) , S35-S38
Improving long-term follow-up studies of immunomodulatory therapies
Goals in the treatment of multiple sclerosis (MS) focus on reducing symptoms and disease progression. Registry data indicate that the accumulation of significant disability can take decades. Therefore, long-term follow-up (LTFU) studies are needed to understand the impact of disease-modifying therapy (DMT) in MS. Based on analyses of available LTFU study data, recommendations for future LTFU studies can be made. A disability milestone may be considered because exploratory data show that DMT may slow the progression of disability. Achievement of the EDSS steps 4 or 6 may be sufficient milestones because, once reached, MS progresses inevitably. Since a placebo control cannot be ethically used in LTFU studies, a standard-of-care comparator could be considered. The ideal LTFU study should be performed according to the highest possible standards. A high-quality LTFU study would achieve high retention rates, capture complete data at prespecified assessment intervals, and be powered to the key outcome measure. In addition, propensity scoring is an approach used to reduce bias in treatment comparisons in observational studies and might be a suitable approach for analyzing LTFU studies. With careful consideration of LTFU limitations and study design, it is possible to attain a high degree of rigor in future studies.
- Open Access
- 19 January 2010
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 16 (4) , 503-510
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group
Current therapies for multiple sclerosis effectively reduce inflammation, but do little in terms of repair to the damaged central nervous system. Cell-based therapies may provide a new strategy for bolstering regeneration and repair through neuro-axonal protection or remyelination. Mesenchymal stem cells modulate pathological responses in experimental autoimmune encephalitis, alleviating disease, but also stimulate repair of the central nervous system through the release of soluble factors. Autologous and allogeneic mesenchymal stem cells have been safely administered to individuals with hemato-oncological diseases and in a limited number of patients with multiple sclerosis. It is therefore reasonable to move mesenchymal stem cells transplantation into properly controlled human studies to explore their potential as a treatment for multiple sclerosis. Since it is likely that the first such studies will probably involve only small numbers of patients in a few centers, we formed an international panel comprising multiple sclerosis neurology and stem cell experts, as well as immunologists. The aims were to derive a consensus on the utilization of mesenchymal stem cells for the treatment of multiple sclerosis, along with protocols for the culture of the cells and the treatment of patients. This article reviews the consensus derived from our group on the rationale for mesenchymal stem cell transplantation, the methodology for generating mesenchymal stem cells and the first treatment protocol for multiple sclerosis patients.
- 19 January 2010
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 16 (4) , 503-510
Open AccessThe therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group
Current therapies for multiple sclerosis effectively reduce inflammation, but do little in terms of repair to the damaged central nervous system. Cell-based therapies may provide a new strategy for bolstering regeneration and repair through neuro-axonal protection or remyelination. Mesenchymal stem cells modulate pathological responses in experimental autoimmune encephalitis, alleviating disease, but also stimulate repair of the central nervous system through the release of soluble factors. Autologous and allogeneic mesenchymal stem cells have been safely administered to individuals with hemato-oncological diseases and in a limited number of patients with multiple sclerosis. It is therefore reasonable to move mesenchymal stem cells transplantation into properly controlled human studies to explore their potential as a treatment for multiple sclerosis. Since it is likely that the first such studies will probably involve only small numbers of patients in a few centers, we formed an international panel comprising multiple sclerosis neurology and stem cell experts, as well as immunologists. The aims were to derive a consensus on the utilization of mesenchymal stem cells for the treatment of multiple sclerosis, along with protocols for the culture of the cells and the treatment of patients. This article reviews the consensus derived from our group on the rationale for mesenchymal stem cell transplantation, the methodology for generating mesenchymal stem cells and the first treatment protocol for multiple sclerosis patients.
- Open Access
- 6 October 2009
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 15 (10) , 1133-1134
‘Time is brain’ also in multiple sclerosis
- 6 October 2009
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 15 (10) , 1133-1134
Open Access‘Time is brain’ also in multiple sclerosis
- 13 August 2009
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 25 (10) , 2459-2470
Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command
The therapies available today for multiple sclerosis (MS) reduce but do not fully control disease activity. The objective of this article is to review the definitions of and treatments for suboptimally controlled MS and highlight the challenges faced by clinicians to increase awareness of recognizing and managing patients with suboptimally controlled MS. Published literature describing treatment failure, treatment optimization paradigms or algorithms, clinical studies of therapies in patients with suboptimally controlled MS, or case reports of management of patients with suboptimally controlled MS were identified from searches of EMBASE and MEDLINE. This was supplemented with case reports and discussions from an expert panel meeting of MS specialists focused on the diagnosis and treatment of suboptimally controlled MS. Several groups have created recommendations for evaluating suboptimal response to disease-modifying drugs (DMDs) in MS. Currently no robust evidence-based data exist to guide treatment decisions in patients who have suboptimal response to a particular therapy. In the absence of data, several treatment paradigms for suboptimally controlled MS have been proposed using a step therapy or platform therapy approach. Therapy modifications require consideration of disease- and patient-specific factors while accounting for the risk-benefit profile of the agent(s). Unapproved drugs and combination therapies should be reserved as agents of last resort because of the experimental nature of these treatments. In the absence of evidence-based data, identifying and treating MS patients with suboptimal response to the available platform therapies remains challenging. Developing algorithms able to quantify breakthrough disease activity and suboptimal response to DMDs in individual MS patients remains an important target for the MS community. Consideration should be given for all reasons why a particular DMD may not be working for a given patient and for the use of an individualized step therapy.
- 13 August 2009
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 25 (10) , 2459-2470
Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command
The therapies available today for multiple sclerosis (MS) reduce but do not fully control disease activity. The objective of this article is to review the definitions of and treatments for suboptimally controlled MS and highlight the challenges faced by clinicians to increase awareness of recognizing and managing patients with suboptimally controlled MS. Published literature describing treatment failure, treatment optimization paradigms or algorithms, clinical studies of therapies in patients with suboptimally controlled MS, or case reports of management of patients with suboptimally controlled MS were identified from searches of EMBASE and MEDLINE. This was supplemented with case reports and discussions from an expert panel meeting of MS specialists focused on the diagnosis and treatment of suboptimally controlled MS. Several groups have created recommendations for evaluating suboptimal response to disease-modifying drugs (DMDs) in MS. Currently no robust evidence-based data exist to guide treatment decisions in patients who have suboptimal response to a particular therapy. In the absence of data, several treatment paradigms for suboptimally controlled MS have been proposed using a step therapy or platform therapy approach. Therapy modifications require consideration of disease- and patient-specific factors while accounting for the risk-benefit profile of the agent(s). Unapproved drugs and combination therapies should be reserved as agents of last resort because of the experimental nature of these treatments. In the absence of evidence-based data, identifying and treating MS patients with suboptimal response to the available platform therapies remains challenging. Developing algorithms able to quantify breakthrough disease activity and suboptimal response to DMDs in individual MS patients remains an important target for the MS community. Consideration should be given for all reasons why a particular DMD may not be working for a given patient and for the use of an individualized step therapy.
- Open Access
- 20 May 2009
- Published by Springer Nature in BMC Neurology
- Vol. 9 (1) , 19
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
To diagnose multiple sclerosis (MS), evidence for dissemination in space and time is required. There is no clear definition on how symptoms and signs of a patient indicate clinical dissemination in space. To provide a uniform approach on this subject, a clinical classification system was described recently differentiating patients with mono- and multifocal clinical presentation. Here we assess the predictive value of clinically defined dissemination in space at first presentation for time to clinically definite MS (CDMS).
- 20 May 2009
- Published by Springer Nature in BMC Neurology
- Vol. 9 (1) , 19
Open AccessMRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
To diagnose multiple sclerosis (MS), evidence for dissemination in space and time is required. There is no clear definition on how symptoms and signs of a patient indicate clinical dissemination in space. To provide a uniform approach on this subject, a clinical classification system was described recently differentiating patients with mono- and multifocal clinical presentation. Here we assess the predictive value of clinically defined dissemination in space at first presentation for time to clinically definite MS (CDMS).